Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the…

This article was originally published here

Mol Brain. 2021 May 7;14(1):76. doi: 10.1186/s13041-021-00787-6.


Amyotrophic lateral sclerosis (ALS) is a neurodegenerative fatal disorder in which motor neurons within the brain and spinal cord degenerate. A single infusion of mesenchymal stem cells (MSCs) delays disease progression by protecting motor neurons and restoring the blood-spinal cord barrier in the SOD1G93A transgenic ALS rat model. However, the therapeutic effect of a single infusion of MSCs is transient and does not block disease progression. In this study, we demonstrated that repeated administration of MSCs (weekly, four times) increased the survival period, protected motor functions, and reduced deterioration of locomotor activity compared to a single infusion and vehicle infusion, after which rats displayed progressive deterioration of hind limb function. We also compared the days until gait ability was lost in rats and found that the repeated-infused group maintained gait ability compared to the single-infusion and vehicle-infusion groups. These results suggest that repeated administration of MSCs may prevent the deterioration of motor function and extend the lifespan in ALS.

PMID:33962678 | DOI:10.1186/s13041-021-00787-6

View original post here:

Repeated infusion of mesenchymal stem cells maintain the condition to inhibit deteriorated motor function, leading to an extended lifespan in the...

Read more
Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary…

Phase 1/2 Trial to Begin By Fall 2021 at a Top US Cancer Center

PARIS, May 10, 2021 (GLOBE NEWSWIRE) -- Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic thymus in a dish technology to develop proprietary allogeneic T cell progenitor product SMART 101 (ProTcell) for rapid reconstitution of T cell immunity, announced today that its Investigational New Drug (IND) for Acute lymphocytic leukemia (ALL) and Acute myelocytic leukemia (AML) has been accepted by the FDA. The FDA has also granted SMART 101 fast-track designation under its Expedited Program for Serious Conditions. Previously, the FDA granted orphan drug designation for SMART 101 (ProTcell) as a treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant (HSCT). This orphan drug status encompasses various conditions such as hematologic malignancies like AML and ALL, along with all forms of primary immunodeficiencies including, but not limited to severe combined immunodeficiency (SCID).

The acceptance of the IND by the FDA marks the start of Smart Immunes clinical development program in the U.S. whereby ProTcell will be investigated both as allogeneic non- engineered T cell progenitor medicine in diseases where overall survival and outcome is highly dependent on immediate immune reconstitution after HSCTs, and potentially as engineered T cell therapy. Representing a decade of research and development, this is the first ever IND of any T cell progenitor product in the U.S. The ALL/AML IND encompasses a clinical trial across adult and pediatric leukemia patients receiving T cell depleted allo-HSCT and will initially enroll up to 36 patients. In this phase 1/2 clinical trial, safety and efficacy of ProTcell to rapidly give rise to T cell compartment in order to reduce infections, Graft versus Host Disease (GvHD), and eventually also 1-year non relapse mortality, will be assessed. If successful in clinical development, ProTcells could make Human Leucocyte Antigen (HLA) mismatched transplants as successful as HLA-identical, with the benefit of rapid immune-reconstitution and patient recovery and discharge.

These U.S. Smart Immune sponsored adult and pediatric leukemia studies will run in addition to the ongoing European studies of allogeneic ProTcell for:

From refining this technology at the Necker Childrens Hospital in Paris for over a decade, to finally treating patients, I am proud of our journey and of the therapeutic versatility of these allogeneic T cell progenitorswhich should be able to reset rapidly a polyclonal T cell compartment, said Pr. Marina Cavazzana, physician and co-founder of Smart-Immune. As we treat very sick patients and hope to durably reconstitute their fragile immune systems, we plan to be cautious and measured in our development path starting with establishing unequivocal clinical proof of the efficacy and safety of our ProTcell that are devoid of any genetic engineering in this first phase of our development. Such proof can then pave the way for a more expedited clinical development of genetic engineered ProTcell in the future.

The clinical trials that are part of the FDA accepted U.S. IND are on track to begin in fall of 2021. Full clinical design of the trials, its clinical center and lead investigators will be announced and become available on prior to the start of the study.

About Smart ImmuneSmart Immune was founded in 2017 by three women Dr. Isabelle Andr, Pr. Marina Cavazzana and Karine Rossignol around groundbreaking scientific work at the Imagine Institute of Genetic Diseases and Necker Enfants Malades Hospital over more than 10 years. Pr. Marina Cavazzana is known as a pediatric Hematologist and a pioneer in vector-based therapies and hematopoietic stem cell treatments. The Company is utilizing its unique ex-vivo biomimetic thymus in a dish technology to culture specific T cell progenitor subpopulations that are so short-lived in nature that until now they were unculturable at scale. These therapeutic T cells progenitor (ProTcell) are cultured without exogenous genetic engineering, and designed to empower the human immune system to fight infections and eradicate malignant disease from the body.

At first ProTcell will be investigated as adjunct to allo-HSCT with potential to overcome major allo-HSCT challenges like infection and GvHD. By actively reconstituting a fully polyclonal T cell population, ProTcell not only reduces infection and GvHD following HSCT, but also plays a role in fighting the underlying cancer with the potential to reduce relapse related mortality. Smart Immune is initially targeting the pediatric orphan indication Severe Combined Immune Deficiency (SCID) & oncology (AML). To learn more, please visit

Media/Investor ContactJason WongBlueprint Life Science 375-3340 Ext. 4

See the original post here:

Smart Immune Announces FDA Orphan Drug Status, IND Acceptance and Fast-Track Designation to Commence Phase 1/2 Clinical Trial of Proprietary...

Read more
Nathaniel’s family have just three days to raise 150,000 for life-saving operation – Mirror Online

Simon Cowell and David Walliams are backing our campaign to save Nathaniel Nabena as his family race to raise 150,000 in three days.

The big-hearted Britains Got Talent stars have each given five-figure sums to help the nine-year-old, after we revealed his parents must raise 201,000 by Wednesday for a life-saving stem cell transplant.

Manchester United and Marvel fan Nathaniel is not entitled to free NHS treatment because he is not a British national.

He was diagnosed with acute myeloid leukaemia in the UK after flying here for a 5,000 prosthetic eye fitted privately after losing it to a tumour in his home country Nigeria.

Simon, 61, whose son Eric is seven, said: This must be a really difficult time for Nathaniel and his parents, lets all pray that this campaign gets Nathaniel the treatment he needs.

Comedian David, 49, dad to Alfred, aged eight, said: Nathaniel is a very special little boy and we must do everything we can to ensure he gets all the treatment he needs so he can enjoy a long and happy life.

Generous Sunday People readers helped raise 87,000 earlier this year for three rounds of chemo at Great Ormond Street Hospital in March to get him in shape for the life-saving op.

He responded better than consultants expected and is in remission and in a position for a transplant, using donor stem cells from an umbilical cord.

Readers have helped raise another 30,000 last week to fund transplant procedure and doctors at GOSH have kindly waived their private fees to reduce the cost. But there is still another 150,000 to find.

Consultants at GOSH say his cancer could return at any time and the window for a successful op while chemotherapy is keeping the cancer at bay means the cash must be raised by Wednesday.

After that, the chances of it working will be reduced, and Nathaniels only likely option will be palliative care.

A host of stars have rallied around to support Nathaniel as the family race to raise cash.

Former JLS singer Aston Merrygold, Paul OGrady and Loose Womens Coleen Nolan were among those backing the lad.

Dad-of-two Aston, 33, shared the appeal with his 427k Instagram followers, urging them: Please help Nathaniels family.

Reality star Katie Price shared a fundraising page with her 2.5 million Instagram followers and called for fans to give Nathaniel the chance for a life.

Nathaniel said he is so grateful for the support from readers and celebs.

He said: Thank you all, everybody, for helping me and giving me a chance at life.

"God bless everybody.

His parents Ebi, 45, and Modupe, 38, have been moved to tears by the support from stars and People readers.

Ebi said: Ive been crying knowing that the British people have given my son another hope in life again when all hope was gone. It is like a modern day miracle. We are so grateful.

We all watch American Idol as a family and Nathaniel watches videos of Simon on TikTok. He is a big fan.

"To David we say, thank you so much for coming to the aid of a stranger and being a Good Samaritan.

"We have still got to raise three-quarters of what we need.

"I have not been able to sleep, I worry so much about how we are going to raise the money. It is so tough.

This week, Nathaniel had tests and saw a psychologist at GOSH ahead of the potential transplant and rested at his relatives home in Croydon, South London.

Ebi said: So far the test results have been wonderful. Hes in top shape, hes doing so well. Hes been playing his video games.

He knows hes going to be in hospital for a long time and expressed his fears in a meeting with a psychologist. We are doing our best to reassure him.

Nathaniel has already overcome a lot after having his left eye removed last September while fighting another cancer, myeloid sarcoma, in southern Nigeria.

His family raised 5,000 so he could travel with Ebi to London to have a prosthetic fitted at Londons Moorfield Eye Hospital in November.

Within days of arriving Nathaniel suffered nosebleeds and a fever and was rushed to Croydon University Hospital where he was diagnosed with terminal AML, which affects around 100 children every year in the UK.

It is so aggressive he could have died within weeks without chemo.

His family were initially told the total cost of the treatment at GOSH would be up to 825,000.

Celebrities have voiced their concern for Nathaniel after learning of his desperate situation.

Corrie legend Beverley Callard: This little boy deserves all the help we can give him, so lets dig deep and get him the treatment he needs to save his life.

Emmerdales Claire King: Please, please help Nathaniels family raise 150,000. Stay strong, Nathaniel. We are all wishing you the very best.

Coleen Nolan, Loose Women panellist: What Nathaniel is going through is every familys worst nightmare. They are so close to the treatment he desperately needs, and the kindness of strangers can help him.

Benidorms Sherrie Hewson: Every child deserves the best chance at life, and while there is hope for Nathaniel, we mustnt give up. He has shown such bravery coming this far and now he needs a chance at the treatment that could save him. I hope everyone will get behind this courageous little boy and his family to donate and give him a future.

Samantha Giles, Hollyoaks actress: If you can manage to donate just a pound, it could potentially save Nathaniels life. Thank you, thank you! Youve done something wonderful.

Entrepreneur and presenter Saira Khan: If we can all give a little bit, we can help to save this little boys life.

TV and stage star Claire Sweeney: GOSH consultants have graciously waived their fee, but we still need to raise 150,000 for a life-saving stem cell treatment. Please dig deep we only have three days to save this beautiful boy.

The transplant treatment is not available in his home country and he was too sick to travel.

Ebi and Modupe were in despair when they first spoke to us three months ago.

But Sunday People readers stepped in to raise 87,000 for chemo which has given him a chance of surviving a transplant.

Clinicians have lowered costs after Nathaniel responded better than expected to treatment and needed less chemo.

And last week we revealed consultants at GOSH have waived their private fees to help Nathaniel.

The 201,103 covers the donor stem cell transplant and the cost of care, excluding consultants fees, based on a typical inpatient admission of eight weeks and a three-month post-transplant follow-up as an outpatient.

Professor Ajay Vora, a consultant paediatric haematologist at GOSH, said: All the consultants involved in his care are working in a private capacity and have waived their fee because they want to help him.

Our time is not borrowed from the NHS because we are treating Nathaniel in our private service in our time.

If enough is raised for the transplant, Nathaniel will undergo tests to begin the process on Friday, May 14.

Doctors had hoped to have a bone marrow transplant from one of his two sisters Nadia, 11, and Nicole, 21 months.

But they were not a match.

Ebi said: Even to get to this point where we may have access to treatment is a miracle.

"Wed given up hope.

The mum of a girl who was saved by a stem cell transplant five years ago has urged readers to back Nathaniel.

Marie Stark said energetic Ava who loves anything that involves running around is a testament to what the procedure can do.

She said: The fact his family is having to raise money while theyre so worried about him, I cant even imagine how hard that is. I remember that desperation, of wanting to do whatever you can to save your child.

Aged three, Ava was diagnosed with blood disorder aplastic anemia and had just months to live if no stem cell donor was found.

Her plight sparked a nationwide search, with Marie, a car rental worker, describing the race to save her girl as a ticking time bomb.

Ava, of Lochgelly, Fife, had a transplant in late 2016. Now eight, Ava loves riding her scooter, walking her dogs and trampolining.

Marie, 38, who was supported by blood cancer charity Anthony Nolan, said: I know first hand the good a stem cell transplant can do. If everybody gave 50p or 1 there would be so much money there to help Nathaniel.

Join the stem cell register:

See the rest here:

Nathaniel's family have just three days to raise 150,000 for life-saving operation - Mirror Online

Read more
Global Stem Cell manufacturing Market with Covid 19 Analysis and Challenges On Upcoming Trends 2021-2028 The Courier – The Courier

This market report involves the drivers and restraints for Global Stem Cell manufacturing Market that are derived from SWOT analysis and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the market are by systemic company profiles. The market data within the report is displayed in a statistical format to offer a better understanding upon the market dynamics. This report provides granular analysis of the market share, segmentation, revenue forecasts and geographic regions of the market

The Global Stem Cell manufacturing Market is expected to reach USD 16.51 Billion by 2025, from USD 10.28 Billion in 2017 growing at a CAGR of 6.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Download PDF sample copy of this research report@

Top Competitors:

Some of the major players operating in the stem cell manufacturing market are:-

Market Definition:

This market report defines the market trends and forecast the upcoming opportunities and threats of the stem cell manufacturing market in the next 8 years. Stem cell manufacturing is a process of extracting the cells either from bone marrow or peripheral blood cells and culturing the cells in the culture dish containing nutrient media. Stem cells can be isolated from umbilical cord blood, placenta, amniotic sac, amniotic fluid, adipose tissue and menstrual blood. Stem cell manufacturing is used in the cell therapy as well as in gene therapy. Stem cell therapy is under research for many diseases like degenerative diseases and hematopoietic disorders like sickle cell anemia, storage disorders. Now stem cells are also used in making the cell and tissue bank. Some of the cell culture banks are National Institute of Biomedical Innovation, Health and Nutrition and World Federation for Culture Collections.

Talk to our experts @

Major Market Drivers:

Inquire before Buying @

Key Questions Answered inGlobal Stem Cell Manufacturing Market Report:-

What will the marketgrowth rate, Overview and Analysis by Type of Global Stem Cell Manufacturing Market in 2025?

What are thekey factors driving, AnalysisbyApplicationsandGlobal Stem Cell Manufacturing Market?

What areDynamics, This Overview IncludesAnalysis of Scope, andprice analysis of top Vendors Profiles of Global Stem Cell Manufacturing Market?

Who areOpportunities, Risk and Driving Forceof Global Stem Cell Manufacturing Market?

Who are theopportunities and threats faced by the vendorsinGlobal Stem Cell Manufacturing Market?

What are the Global Stem Cell Manufacturing Market opportunities,market risk and market overviewof the Market?

Read More @

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.


Data Bridge Market Research

Tel: +1-888-387-2818


See original here:

Global Stem Cell manufacturing Market with Covid 19 Analysis and Challenges On Upcoming Trends 2021-2028 The Courier - The Courier

Read more
Stem Cell Therapies Becoming a Common Treatment for Medical Diseases, Disorders and Traumas – Flagstaff Business News

If you have an injury, or if you have tendons or ligaments that have become inflamed, stem cell therapy may help.

Why Choose Stem Cell Therapy?

As with other cells in our body, stem cells also age as we do. That is why we provide stem cells that are derived from umbilical cord tissue/blood. This is a natural healing therapy with cells that are native to our body.

Our Regenerative Stem Cell injections are derived from an umbilical cord tissue/blood product that captures all the greatest regenerative properties of this otherwise discarded tissue. Our brand of Stem Cell injectables uses a proprietary method of isolating growth factors, cells and stem cells, giving our patients the best possible benefits from a regenerative medicine product. The use of cells, stem cells and growth factors have all shown to be one of the best therapeutic methods to help aid in tissue healing and repair.

Mesenchymal stem cells, or MSCs, are multipotent stromal cells (a type of cell that makes up certain types of connective tissue) that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells).

Our regenerative medicine product is produced in compliance with FDA CGMP (Current Good Manufacturing Practice) and GTP (Good Tissue Practices) standards, which assures quality and safety in this product.

Research has shown that umbilical cord-derived stem cells are not susceptible to malignant transformation in a serum-free medium, making them safe for therapeutic use in patients for cell therapy.

How Does It Work?

Stem cells have the capacity to migrate to injured tissues, a phenomenon called homing. This occurs by injury/disease signals that are released from the distressed cells/tissue. Once stem cells are delivered to a site of injury or deployed into the bloodstream, they go to these distressed signals and dock on adjacent cells to commence performing their job.

If you have an injury, or if you have tendons or ligaments that have become inflamed, stem cell therapy may help. It uses your bodys own stem cells to help heal damage. It may help you avoid surgery. Learn more at FBN

By Dorian Lange

Dorian Lange, CEO, Northern Arizona Pain Institutes Dorian is responsible for the management, administration and business development for multi-disciplinary specialty clinics throughout central Arizona that provides integrative treatment protocols for pain management, physical and rehabilitative medicine. Developed the initial business plan and implemented the strategic planning from startup to a multi-million-dollar medical specialty organization. Learn more at

Read this article:

Stem Cell Therapies Becoming a Common Treatment for Medical Diseases, Disorders and Traumas - Flagstaff Business News

Read more
Global Cord Blood Stem Cells Market by Type (Allogeneic Stem Cell, Autologous Stem Cell), By Application (Autoimmune Diseases, Immunodeficiencies,…

Industry Growth Insights published a new data on Cord Blood Stem Cells Market. The research report is titled Cord Blood Stem Cells Market research by Types (Allogeneic Stem Cell, Autologous Stem Cell), By Applications (Autoimmune Diseases, Immunodeficiencies, Malignancies,Caners, Solid Tumors, Others), By Players/Companies Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., Athersys Inc., Geron Corporation, Neostem Inc., CBR Systems, Inc., Cordlife, Cryo-Cell, Cryo-Save AG (A Group of Esperite), Lifecell, Stemcyte, Viacord, Smart Cells International Ltd., Cryoviva India, Cordvida, China Cord Blood Corporation. As per the latest research Cord Blood Stem Cells market is expected to expand at a CAGR of xx% in the forecast period.

Report Attributes

Report Details

Report Title

Cord Blood Stem Cells Market Research Report

By Type

Allogeneic Stem Cell, Autologous Stem Cell

By Application

Autoimmune Diseases, Immunodeficiencies, Malignancies,Caners, Solid Tumors, Others

By Companies

Advanced Cell Technology, California Stem Cell, Cytori Therapeutics, Mesoblast Limited, Opexa Therapeutics Inc., Athersys Inc., Geron Corporation, Neostem Inc., CBR Systems, Inc., Cordlife, Cryo-Cell, Cryo-Save AG (A Group of Esperite), Lifecell, Stemcyte, Viacord, Smart Cells International Ltd., Cryoviva India, Cordvida, China Cord Blood Corporation

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2018 to 2019 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

The global Cord Blood Stem Cells market is segmented on the basis of:


Allogeneic Stem Cell, Autologous Stem Cell

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Autoimmune Diseases, Immunodeficiencies, Malignancies,Caners, Solid Tumors, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

We have studied the Cord Blood Stem Cells Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

Regional Analysis

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

8 Reasons to Buy This Report

The rest is here:

Global Cord Blood Stem Cells Market by Type (Allogeneic Stem Cell, Autologous Stem Cell), By Application (Autoimmune Diseases, Immunodeficiencies,...

Read more
Our first child is due, and Im already in the clutches of the baby-industrial complex – The Guardian

A boob. A bed. Maybe a bottle? In the early days of my wifes pregnancy, I naively thought that was all a newborn baby would really need. After all, all they do is eat, poop, sleep, repeat. You dont need an arsenal of complicated equipment to deal with that, right?

Wrong. Our first child is due imminently and, despite my best efforts to escape the evil clutches of the baby-industrial complex, our tiny New York apartment is stuffed with weird stuff. Reader, I have a snot-sucker. Thats not a euphemism thats a real thing you use to suck mucus out of a childs nose. I asked a friend with kids: Seriously? Do I actually need this? She gave me a look a lot of parents have been giving me recently. Its a look that says: Damn, you really dont know what youre in for.

I havent just become a person who owns a snot-sucker. Im dismayed to say that I have become a person who knows far too much about the Snoo. The Snoo being a $1,495 (1,145) artificial-intelligence-powered bassinet that uses algorithms to respond to a baby fussing and rock it back to sleep. You absolutely need a Snoo, some people have told me. Its a huge waste of money, others have said. Its like the Marmite of baby gear. Just a hell of a lot more expensive.

While you may need slightly more than a boob and a bed to raise a kid, you dont need an AI-powered crib to be a good parent. In Finland, supposedly the worlds happiest country, new parents are sent home from hospital with a government-issue cardboard box for their babies to sleep in. (In the US, which has the most miserable parents in the western world, according to a 2016 study, youre sent home from hospital with a massive bill.) Nevertheless, being an expectant parent means being bombarded with ads that guilt-trip you into spending money unnecessarily. For example, we recently got a pamphlet through the post urging us to store our newborns cord blood in a private bank in case she develops a condition that can be treated with her own stem cells. The chances of that happening are negligible, but what if it does? If you dont cough up, you dont care about your kids life. The whole thing feels predatory and disgusting. Particularly as its far better to donate that cord blood to a public bank where theres more of a chance it may help someone.

Its not just the expensive cribs and the weird blood banks that get your head spinning, its the endless conflicting baby advice. Stick to a strict routine, or theyll turn into a monster! Dont stick to a schedule, or theyll become neurotic! If you let your kid cry it out, theyll turn into a sociopath who is incapable of forming secure attachments! If you dont let them cry it out, theyll never learn how to be independent!

For a hot second, I thought I ought to get into the baby advice business myself; it seemed like a lucrative career move. At one point, I decided to trial in-utero sleep training and then patent my amazing technique. Anyway, I got tired of that after about five days of playing the same song next to my partners belly at bedtime. Then I thought I would teach the kid the times tables while she was still in the womb. That plan was foiled when I realised, with horror, that I wasnt sure I could remember all my times tables. Now I have decided that the best thing I can possibly do to prepare for parenthood is just try not to worry too much and perhaps brush up on my times tables.

Arwa Mahdawi is a Guardian columnist.

Continue reading here:

Our first child is due, and Im already in the clutches of the baby-industrial complex - The Guardian

Read more
Scientists identify small-molecule cocktail to improve stem cell use in research and disease treatments – National Institutes of Health

News Release

Monday, May 3, 2021

Researchers at the National Institutes of Health have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function. The researchers suggest that the cocktail could enhance the potential therapeutic uses of stem cells, ranging from treating diseases and conditions such as diabetes, Parkinsons disease and spinal cord injury to genome editing.

Human pluripotent stem cells are cells that, in theory, can grow forever and serve as an inexhaustible source for specialized cells, such as brain, kidney and heart cells. But stem cells are sensitive, and their potential uses in medicine are hampered by the stress of growing in a cell culture dish, which can damage their DNA and lead to cell death.

In a series of experiments, scientists led by Ilyas Singe, M.D., Ph.D., director of the Stem Cell Translation Laboratory at NIHs National Center for Advancing Translational Sciences (NCATS), used high-throughput screening to systematically test thousands of compounds and drugs to identify a unique combination that greatly improved stem cell survival and reduced cell culture stress. Singe and his co-investigators described how they developed the cocktail, called CEPT, and its potential applications May 3 in Nature Methods.

The small-molecule cocktail is safeguarding cells and making stem cell use more predictable and efficient. In preventing cellular stress and DNA damage that typically occur, were avoiding cell death and improving the quality of surviving cells, said Singe. The cocktail will become a broadly used staple of the stem cell field and boost stem cell applications in both research and the clinic.

iPSCs are derived from reprogrammed skin or blood cells. To improve their survival in culture, Singe and his team initially tested more than 15,000 U.S. Food and Drug Administrationapproved drugs and investigational small-molecule compounds from NCATS collections. Among the 20 drugs and compounds that could inhibit the activity of ROCK, a type of kinase enzyme that is involved in stem cell stress, they found that the compound Chroman 1 was more potent than the widely used compound Y27632 in improving cell survival.

To further improve cell survival, Singe and his colleagues used NCATS matrix drug screening capabilities to look for potential synergies between Chroman 1 and other drugs and compounds. Matrix drug screening enables investigators to study the effects of drug combinations and determine possible mechanisms by which these drugs act. The researchers identified an investigational drug, Emricasan, that, when combined with Chroman 1, could provide additional support to improve stem cell viability.

According to Singe, an important effort in stem cell biology is an experimental process called single-cell cloning. Although culturing stem cells in large groups is easier, single-cell cloning culturing one cell at a time in a tiny well of a cell culture plate is very stressful to cells and inefficient. The process has critical applications in gene editing and establishing cell lines, which are cell cultures developed from a single cell.

In its initial screening work, the team tested the protective effects of drugs and compounds on 500 stem cells at a time in plate wells. To mimic the cell stress seen during single-cell cloning, the researchers then developed a new assay (test) to allow them to examine the effects of more than 7,500 compounds on only 10 cells at a time.

This testing led to the identification of a third compound, trans-ISRIB, that enhanced cell survival, even when there were few cells in each plate. Additional experiments showed that a mixture of compounds called polyamines in combination with Chroman 1, Emricasan and trans-ISRIB proved best for single-cell cloning.

Cells need to be cultured properly, and they have to be of good quality to go into patients, said NCATS Acting Director Joni Rutter, Ph.D. By finding new ways to protect stem cells from damage, these results could eventually have wide-ranging implications for many different diseases, including cancer, Alzheimers disease and more.

The team carried out an array of experiments to test the usefulness of the cocktail. The researchers showed, for example, that CEPT improved the biobanking of stem cells, called cryopreservation, which involves freezing the cells and typically is very stressful for them. Cryopreservation is critical to bringing stem cells to the clinic, but significant numbers of cells are lost or damaged during the thawing process. The cocktail dramatically improved the process.

In another test, the researchers studied the use of the cocktail on iPSCs that already were differentiated into heart cells, motor neurons and other cell types. They found that these more differentiated cells treated with CEPT also were more viable and showed improved function. Singe also noted potential uses for the cocktail in tissue engineering and the biomanufacturing of various cell types for regenerative medicine and drug development.

For the last 20 years, we have not been able to culture human stem cells in the most optimal conditions, Singe said. Our approach could improve safety and ensure that the next-generation stem cell lines are cultured at high quality before moving into the clinic.

The research was funded in part by the Regenerative Medicine Program of the NIH Common Fund and in part by the NCATS intramural research program.

About the National Center for Advancing Translational Sciences (NCATS):NCATS conducts and supports research on the science and operation of translation the process by which interventions to improve health are developed and implemented to allow more treatments to get to more patients more quickly. For more information about how NCATS helps shorten the journey from scientific observation to clinical intervention, visit

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit

NIHTurning Discovery Into Health


Read this article:

Scientists identify small-molecule cocktail to improve stem cell use in research and disease treatments - National Institutes of Health

Read more
Hematopoietic Stem Cell Transplantation (HSCT) Market Trend, Technology Innovations and Growth Prediction 2020-2025 – AlgosOnline

Date: 2021-05-03 Author: Ashwin NaphadeCategory: #market

According to business intelligence report on Hematopoietic Stem Cell Transplantation (HSCT) market, Covid-19 pandemic will have lasting impact on industry sphere, based on which growth matrix for 2020-2025 is formulated.

The Hematopoietic Stem Cell Transplantation (HSCT) market report is a comprehensive documentation of the prevalent industry trends and aims to educate the readers about competitive scenario and regional business dynamics. It leverages the expert verbatim to warn about challenges dormant in the industry, while providing insights about the profitable opportunities across various market segments. Moreover, the study entails numerous scenarios, including COVID-19 impact, hence enabling companies to formulate contingency plans and stakeholders to take informed decisions.

Request a sample Report of Hematopoietic Stem Cell Transplantation (HSCT) Market at:

Takeaways from COVID-19 impact scrutiny:

Summary of regional landscape:

Ask for Discount on Hematopoietic Stem Cell Transplantation (HSCT) Market Report at:

Other highlights from Hematopoietic Stem Cell Transplantation (HSCT) market report:

Report Objectives:

For More Details On this Report:

Related Reports:

1. 2020-2025 Global Print and Apply Labeling Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)Read More:

2. 2020-2025 Global Hyperthermia Instrument Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)Read More:

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Read More:

Read this article:

Hematopoietic Stem Cell Transplantation (HSCT) Market Trend, Technology Innovations and Growth Prediction 2020-2025 - AlgosOnline

Read more
Stem Cell Therapy Market: Research Report By Scope, Size, Share, Drivers, Restraints, Key Players and Forecasts KSU | The Sentinel Newspaper – KSU |…

The Stem Cell Therapy Market report presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behavior, pricing factors, and market performance and estimation throughout the forecast period. This report lends a hand to identify how the market is going to perform in the forecast years by providing information about market definition, classifications, applications, and engagements. The Stem Cell Therapy Market report also covers geographical markets and key players that have adopted significant strategies for business developments.

Request for FREE Sample Report: To Know the Impact of COVID-19 on this Industry @

Lists of Companies Profiled in the Report:

Primary and secondary research methodologies have been employed for a detailed study to generate this report. Researchers and analysts have also estimated key milestones achieved by the Stem Cell Therapy Market and compared it to the current market trends to give the readers a holistic picture of the market. This report performs a SWOT analysis of major key players of the industry based on strengths, weaknesses, opportunities, and threats as well as the companys internal & external environments. This Stem Cell Therapy Market research report assesses the current as well as future performance of the market, and also brand-new trends in the market.

Rising investments and funding in stem cell research is driving the overall growth of the stem cell therapy market

The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.

The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, by type, during the forecast period

The stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy. Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market. The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.

Bone Marrow-derived MSCs segment accounted for the highest CAGR

Based on the cell source from which stem cells are obtained, the global stem cell therapy market issegmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.

Asia Pacific: The fastest-growing country in the stem cell therapy market

The stem cell therapy market is segmented into North America, Europe, Asia Pacific, RoW. The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.

The primary interviews conducted for this report can be categorized as follows:

Research Coverage:

This report provides a detailed picture of the stem cell therapy market. It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its sub segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.

For More Information or Query or Customization Before Buying, Visit @

View post:

Stem Cell Therapy Market: Research Report By Scope, Size, Share, Drivers, Restraints, Key Players and Forecasts KSU | The Sentinel Newspaper - KSU |...

Read more